Why is Illumina (ILMN) stock up today?

Illumina shares are up 0.61% to $191.20 today (trading in a range of $187.09–$194.18), a modest gain that tracks closely with a generally constructive market backdrop rather than a single company-specific catalyst. The most direct company-related tailwind is a price-target increase from Canaccord Genuity analyst Kyle Mikson, who raised his target on the stock from $140 to $190 while maintaining a Hold rating — a 36% lift in the analyst's implied valuation ceiling that likely attracted fresh attention to the name.

Partially offsetting that positive signal is a legal setback: Element Biosciences announced it prevailed in a German patent case against Illumina, a development that could complicate Illumina's competitive position in one of the world's largest life-sciences markets. Patent disputes in genomic sequencing can affect a company's ability to enforce its own intellectual property or defend market share, though the grounding data does not specify the financial scope of this German ruling.

The broader market is also supportive today, with the S&P 500 (tracked by the ^GSPC index) up 0.38% and the Nasdaq-100 (QQQ) up 1.12%, as investors digest a week that included key inflation data — CPI and Core CPI readings released yesterday — and Fed Chairman Warsh's congressional testimony. A rising tide in tech-adjacent growth stocks tends to carry genomics names like Illumina along.

Looking at fundamentals, Illumina carries a market cap of $28.93B, a trailing P/E (price-to-earnings ratio) of 34.7, and forward P/E of 32.3, with revenue growth of 4.8% and earnings growth of 6.1%. Last quarter, the company posted EPS of $1.15 against an estimate of $1.06, and revenue of $1.09B. The next earnings report is scheduled for July 30, 2026, which represents the next major company-specific catalyst on the near-term horizon.